A Novel Systematic Oxidative Stress Score Predicts the Prognosis of Patients with Operable Breast Cancer

Table 1

Clinical characteristics in the training set and validation set.

Variables	Total ()		Training set ()		Validation set ()		value
	No.	%	No.	%	No.	%
Age							0.252
≤60	1347	85.1	1003	84.5	344	86.9
>60	236	14.9	184	15.5	52	13.1
Multifocality							0.927
Yes	39	2.5	29	2.4	10	2.5
No	1544	97.5	1158	97.6	386	97.5
Histological grade							0.180
I	108	6.8	89	7.5	19	4.8
II	903	57.0	671	56.5	232	58.6
III	572	36.2	427	36.0	145	36.6
VCE							0.307
Yes	558	35.2	410	34.5	148	37.4
No	1025	64.8	777	65.5	248	62.6
T stage							0.371
T1	717	45.3	549	46.2	168	42.4
T2	760	48.0	555	46.8	205	51.8
T3	60	3.8	47	4.0	13	3.3
T4	46	2.9	36	3.0	10	2.5
N stage							0.248
N0	828	52.3	630	53.1	198	50.0
N1	402	25.4	298	25.1	104	26.3
N2	207	13.1	145	12.2	62	15.7
N3	146	9.2	114	9.6	32	8.0
TNM stage							0.263
Stage I	438	27.7	341	28.7	97	24.5
Stage II	744	47.0	549	46.3	195	49.2
Stage III	401	25.3	297	25.0	104	26.3
IHC subtype							0.155
Luminal A	328	20.7	252	21.3	76	19.2
Luminal B	883	55.8	645	54.3	238	60.1
HER2+	184	11.6	139	11.7	45	11.4
TNBC	188	11.9	151	12.7	37	9.3
CRE (μmol/L)							0.544
<59.30	963	60.8	717	60.4	246	62.1
≥59.30	620	39.2	470	39.6	150	37.9
DBIL (μmol/L)							0.326
<2.20	393	24.8	302	25.4	91	23.0
≥2.20	1190	75.2	885	74.6	305	77.0
TBIL (μmol/L)							0.262
<13.80	1270	80.2	960	80.9	310	21.7
≥13.80	313	19.8	227	19.1	86	78.3
LDH (U/L)							0.732
<205.70	1424	90.0	1066	89.8	358	90.4
≥205.70	159	10.0	121	10.2	38	9.6
UA (μmol/L)							0.357
<255.20	408	25.8	299	25.2	109	27.5
≥255.20	1175	74.2	888	74.8	287	72.5
BUN (mmol/L)							0.466
<6.29	1424	90.0	1064	89.6	360	90.9
≥6.29	159	10.0	123	10.4	36	9.1
ALB (g/L)							0.966
<43.00	830	52.4	622	52.4	208	52.5
≥43.00	753	47.6	565	47.6	188	47.5
CRP (mg/L)							0.807
<3.78	1361	86.0	1022	86.1	339	85.6
≥3.78	222	14.0	165	13.9	57	14.4